-
10-222025
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
-
10-152025
Forlong Biotechology Announces Receiving Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Long-acting Technology
-
07-102025
Forlong Biotech Announces CDE Clearance for Phase Ib/II IND of FL115 (IV) Plus PD-1(Sintilimab) in Patients with Advanced Solid Tumors
-
02-152025
Forlong Biotech Announces Dosing First Patient in Phase Ib Trial of FL115 (Intravesical) plus BCG for NMIBC
-
12-262024
Forlong and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of FL115 and Sintilimab in Advanced Solid Tumors
-
08-262024
Forlong Biotech Announces Dosing First Patient in Phase I/II Trial of FL115 (Intravesical Instillation) in patients with NMIBC
-
06-132024
Forlong Biotech Announces Dosing First Patient in Phase I Trial of FL115 (IV) monotherapy in patients with advanced solid tumor
-
12-152023
Forlong Biotechnology Announces Dosing of First Patient in Phase I Clinical Trial of FL115 (IV) Monotherapy, a Best-in-Class-IL15 super agonist
-
11-212023
Forlong biotech and Altruist Biologics Entered into Strategic Alliance to Accelerate Development of Long-Acting Fusion Protein Therapeutics
-
05-212023
Forlong Biotech Announces FDA Clearance for Phase I Clinical Trial of FL115, a Best-in-Class IL-15 Super-Agonist, as IV Monotherapy in Advanced Solid Tumors
-
02-062023
Forlong Biotech Announces $15 Million in Series A Financing to Advance Best-in-Class IL-15 Super Agonist FL115 Into Clinical Trials
苏公网安备32050502011888号